Not applicableStudy completedNCT01281657What this trial is testingLong Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramWho this might be right forMultiple Sclerosis Novartis 64
Post-approval studies (Phase 4)Study completedNCT03784898What this trial is testingCollection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving LemtradaWho this might be right forMultiple Sclerosis Genzyme, a Sanofi Company 13
Not applicableStudy completedNCT06251986What this trial is testingA Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeWho this might be right forRelapsing Forms of Multiple Sclerosis Novartis Pharmaceuticals 310
Not applicableLooking for participantsNCT05658497What this trial is testingPregnancy Exposure Registry for Vumerity (Diroximel Fumarate)Who this might be right forMultiple Sclerosis Biogen 908
Early research (Phase 1)Ended earlyNCT01144351What this trial is testingA Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Elan Pharmaceuticals 32
Post-approval studies (Phase 4)Study completedNCT00536120What this trial is testingThe Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Biogen 60
Post-approval studies (Phase 4)Study completedNCT01216072What this trial is testingA 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forRelapsing Forms of Multiple Sclerosis Novartis Pharmaceuticals 1,053
Large-scale testing (Phase 3)Study completedNCT00472797What this trial is testingRebif New Formulation (RNF) Quality of Life (QOL) StudyWho this might be right forRelapsing Multiple Sclerosis EMD Serono 232
Post-approval studies (Phase 4)Looking for participantsNCT07225361What this trial is testingUblituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisWho this might be right forMultiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting Northwestern University 40
Post-approval studies (Phase 4)Study completedNCT00176592What this trial is testingPhase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRIWho this might be right forMultiple Sclerosis University of Medicine and Dentistry of New Jersey 75
Not applicableStudy completedNCT01080014What this trial is testingCorrelation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaWho this might be right forMultiple Sclerosis Merck KGaA, Darmstadt, Germany 252
Testing effectiveness (Phase 2)Ended earlyNCT00484536What this trial is testingPlacebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323Who this might be right forMultiple Sclerosis UCB Pharma 232
Not applicableActive Not RecruitingNCT05688436What this trial is testingLearn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesWho this might be right forMultiple Sclerosis Biogen 1,178
Large-scale testing (Phase 3)Study completedNCT01199861What this trial is testingEffect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)Who this might be right forRelapsing Multiple Sclerosis Novartis 138
Post-approval studies (Phase 4)Study completedNCT01591551What this trial is testingNAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessWho this might be right forMultiple Sclerosis, Relapsing-Remitting Cornerstone Health Care, PA 37
Testing effectiveness (Phase 2)Study completedNCT03737851What this trial is testingAssess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis (MS) AbbVie 208
Large-scale testing (Phase 3)Study completedNCT01201356What this trial is testingLong-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forRelapsing Forms of Multiple Sclerosis Novartis Pharmaceuticals 4,125
Testing effectiveness (Phase 2)Ended earlyNCT01950234What this trial is testingACTH in Progressive Forms of MSWho this might be right forSecondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis University of Minnesota 59
Not applicableUnknownNCT00914758What this trial is testingComparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)Who this might be right forRelapsing Remitting Multiple Sclerosis Washington Neuropsychology Research Group 1
Very early researchStudy completedNCT00424788What this trial is testingStudy to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)Who this might be right forRelapsing Forms of Multiple Sclerosis Biogen 12